390PA phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women’s cancers
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI